Switdapa 10 mg
Each film-coated tablet contains dapagliflozin
Blister pack of 1 x 15 tablets.
Dapagliflozin is a once-daily oral sglt2 inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus (t2dm). It lowers blood sugar by increasing urinary glucose excretion through inhibition of sodium–glucose cotransporter 2 (sglt2) in the kidney. Beyond glycemic control, dapagliflozin provides additional cardiovascular and renal protection and supports weight loss.
Adults with type 2 diabetes mellitus (≥18 years).
As prescribed by the treating physician or endocrinologist.
Indicated for the management of type 2 diabetes mellitus (t2dm) to improve blood sugar control, lower hba1c, reduce cardiovascular risk, and slow the progression of diabetic kidney disease. Dapagliflozin is also beneficial in patients with heart failure (hfref and hfpef) and chronic kidney disease (ckd) regardless of diabetes status.
Common side effects include genital or urinary tract infections, increased urination, nasopharyngitis, headache, and mild gastrointestinal upset. Hypoglycaemia may occur when used with insulin or insulin secretagogues. Most effects are mild and self-limiting.
Dapagliflozin inhibits renal sodium–glucose cotransporter 2 (sglt2), reducing glucose reabsorption in the proximal renal tubules, thereby promoting urinary glucose excretion, caloric loss, and improved glycemic control. This sglt2 inhibition also promotes osmotic diuresis and natriuresis, contributing to blood pressure reduction, weight loss, and cardiovascular and renal benefits.
